Cognitive Enhancing Drugs in Sport: Current and Future Concerns

References

• Adler, D. (2018). MLB releases annual report on PED testing. https://www.mlb.com/news/mlb-releases-annual-report-on-ped-testing-c301312524
   Google Scholar
• Advokat, C. D., & Scheithauer, M. (2013). Attention-deficit hyperactivity disorder (ADHD) stimulant medications as cognitive enhancers. Frontiers in Neuroscience, 7(82), 82–12. https://doi.org/10.3389/fnins.2013.00082
   PubMedGoogle Scholar
• Bacharach, S. B., Bamberger, P. A., & Sonnenstuhl, W. J. (2002). Driven to drink: Managerial control, work-related risk factors, and employee problem drinking. Academy of Management Journal, 45(4), 637–658. https://doi.org/10.2307/3069302
   Web of Science ®Google Scholar
• Bagot, K. S., & Kaminer, Y. (2014). Efficacy of stimulants for cognitive enhancement in non‐attention deficit hyperactivity disorder youth: A systematic review. Addiction (Abingdon, England), 109(4), 547–557. https://doi.org/10.1111/add.12460
   PubMed Web of Science ®Google Scholar
• Baldwin, A. (2019). Targeted doping tests having an impact in esports, says Verroken. https://uk.reuters.com/article/uk-sport-doping/targeted-doping-tests-having-an-impact-in-esports-says-verroken-idUKKCN1RT2EX
   Google Scholar
• Baranski, J. V., Pigeau, R., Dinich, P., & Jacobs, I. (2004). Effects of modafinil on cognitive and meta‐cognitive performance. Human Psychopharmacology: Clinical and Experimental, 19(5), 323–332. https://doi.org/10.1002/hup.596
   PubMed Web of Science ®Google Scholar
• Battleday, R. M., & Brem, A. K. (2015). Modafinil for cognitive neuroenhancement in healthy non-sleep-deprived subjects: A systematic review. European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology, 25(11), 1865–1881. https://doi.org/10.1016/j.euroneuro.2015.07.028
   PubMed Web of Science ®Google Scholar
• BBC. (2017). Retrieved November 25, 2017, from http://news.bbc.co.uk/2/hi/uk_news/politics/6083840.stm.
   Google Scholar
• Cakic, V. (2009). Smart drugs for cognitive enhancement: Ethical and pragmatic considerations in the era of cosmetic neurology. Journal of Medical Ethics, 35(10), 611–615. https://doi.org/10.1136/jme.2009.030882
   PubMed Web of Science ®Google Scholar
• Caldenhove, S., Sambeth, A., Sharma, S., Woo, G., & Blokland, A. (2018). A combination of nootropic ingredients (CAF+) is not better than caffeine in improving cognitive functions. Journal of Cognitive Enhancement, 2(1), 106–113. https://doi.org/10.1007/s41465-017-0061-0
   Google Scholar
• Campbell-Meiklejohn, D., Simonsen, A., Scheel-Krüger, J., Wohlert, V., Gjerløff, T., Frith, C. D., Rogers, R. D., Roepstorff, A., & Møller, A. (2012). In for a penny, in for a pound: Methylphenidate reduces the inhibitory effect of high stakes on persistent risky choice. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 32(38), 13032–13038. https://doi.org/10.1523/JNEUROSCI.0151-12.2012
   PubMed Web of Science ®Google Scholar
• Caviola, L., & Faber, N. S. (2015). Pills or push-ups? Effectiveness and public perception of pharmacological and non-pharmacological cognitive enhancement. Frontiers in Psychology, 6, 1852. https://doi.org/10.3389/fpsyg.2015.01852
   PubMed Web of Science ®Google Scholar
• Chatterjee, A. (2007). Cosmetic neurology and cosmetic surgery: Parallels, predictions, and challenges. Cambridge Quarterly of Healthcare Ethics, 16(2), 129–137. https://doi.org/10.1017/s0963180107070156
   PubMed Web of Science ®Google Scholar
• Chatwin, C., Measham, F., O'Brien, K., & Sumnall, H. (2017). New drugs, new directions? Research priorities for new psychoactive substances and human enhancement drugs. The International Journal on Drug Policy, 40, 1–5. https://doi.org/10.1016/j.drugpo.2017.01.016
   PubMed Web of Science ®Google Scholar
• Cleveland, E. (2016). What’s missing from the current smart drugs debate? Society, 53(3), 237–239. https://doi.org/10.1007/s12115-016-0006-8
   Web of Science ®Google Scholar
• Connor, J. P., Gullo, M. J., White, A., & Kelly, A. B. (2014). Polysubstance use: Diagnostic challenges, patterns of use and health. Current Opinion in Psychiatry, 27(4), 269–275. https://doi.org/10.1097/YCO.0000000000000069
   PubMed Web of Science ®Google Scholar
• Conrad, E. C., Humphries, S., & Chatterjee, A. (2019). Attitudes toward cognitive enhancement: The role of metaphor and context. AJOB Neuroscience, 10(1), 35–47. https://doi.org/10.1080/21507740.2019.1595771
   PubMedGoogle Scholar
• Copani, A., Genazzani, A. A., Aleppo, G., Casabona, G., Canonico, P. L., Scapagnini, U., & Nicoletti, F. (1992). Nootropic drugs positively modulate alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-sensitive glutamate receptors in neuronal cultures. Journal of Neurochemistry, 58(4), 1199–1204. https://doi.org/10.1111/j.1471-4159.1992.tb11329.x
   PubMed Web of Science ®Google Scholar
• Coveney, C., Williams, S. J., & Gabe, J. (2019). Enhancement imaginaries: Exploring public understandings of pharmaceutical cognitive enhancing drugs. Drugs: Education, Prevention and Policy, 26(4), 319–328. https://doi.org/10.1080/09687637.2019.1593318
   Web of Science ®Google Scholar
• d’Angelo, L., Camilla, S., Savulich, G., & Sahakian, B. J. (2017). Lifestyle use of drugs by healthy people for enhancing cognition, creativity, motivation and pleasure. British Journal of Pharmacology, 174(19), 3257–3267. https://doi.org/10.1111/bph.13813
   PubMed Web of Science ®Google Scholar
• Davis, N. J. (2017). A taxonomy of harms inherent in cognitive enhancement. Frontiers in Human Neuroscience, 11(63), 1–9.
   PubMedGoogle Scholar
• de Jongh, R., Bolt, I., Schermer, M., & Olivier, B. (2008). Botox for the brain: Enhancement of cognition, mood and pro-social behavior and blunting of unwanted memories. Neuroscience and Biobehavioral Reviews, 32(4), 760–776. https://doi.org/10.1016/j.neubiorev.2007.12.001
   PubMed Web of Science ®Google Scholar
• Dietz, P., Soyka, M., & Franke, A. G. (2016). Pharmacological neuroenhancement in the field of economics—Poll results from an online survey. Frontiers in Psychology, 7, 520. https://doi.org/10.3389/fpsyg.2016.00520
   PubMed Web of Science ®Google Scholar
• Dietz, P., Ulrich, R., Dalaker, R., Striegel, H., Franke, A. G., Lieb, K., & Simon, P. (2013). Associations between physical and cognitive doping-a cross-sectional study in 2.997 triathletes. PLOS One, 8(11), e78702. https://doi.org/10.1371/journal.pone.0078702
   PubMed Web of Science ®Google Scholar
• Docherty, J. R. (2008). Pharmacology of stimulants prohibited by the World Anti-Doping Agency (WADA). British Journal of Pharmacology, 154(3), 606–622. https://doi.org/10.1038/bjp.2008.124
   PubMed Web of Science ®Google Scholar
• Dresler, M., Sandberg, A., Bublitz, C., Ohla, K., Trenado, C., Mroczko-Wąsowicz, A., Kühn, S., & Repantis, D. (2019). Hacking the brain: Dimensions of cognitive enhancement. ACS Chemical Neuroscience, 10(3), 1137–1148. https://doi.org/10.1021/acschemneuro.8b00571
   PubMed Web of Science ®Google Scholar
• Dubljević, V., & Ryan, C. J. (2015). Cognitive enhancement with methylphenidate and modafinil: Conceptual advances and societal implications. Neuroscience and Neuroeconomics, 4, 25–33.
   Google Scholar
• Elliott, R., Sahakian, B. J., Matthews, K., Bannerjea, A., Rimmer, J., & Robbins, T. W. (1997). Effects of methylphenidate on spatial working memory and planning in healthy young adults. Psychopharmacology, 131(2), 196–206. https://doi.org/10.1007/s002130050284
   PubMed Web of Science ®Google Scholar
• Esport Integrity Coalition. (2016). Threats to integrity of eSports: A risk assessment (pp. 1–13). ESIC.
   Google Scholar
• Farah, M. J., Illes, J., Cook-Deegan, R., Gardner, H., Kandel, E., King, P., Parens, E., Sahakian, B., & Wolpe, P. R. (2004). Neurocognitive enhancement: What can we do and what should we do? Nature Reviews Neuroscience, 5(5), 421–425. https://doi.org/10.1038/nrn1390
   PubMed Web of Science ®Google Scholar
• Fédération Internationale des Échecs (FIDE). (2018). FIDE anti-doping rules based on Wada’s models of best practice for International Federations and the World Anti-Doping Code. Retrieved May 8, 2020, from https://handbook.fide.com/files/handbook/FIDEAntiDopingRules.pdf
   Google Scholar
• Ferretti, A., & Ienca, M. (2018). Enhanced cognition, enhanced self? On neuroenhancement and subjectivity. Journal of Cognitive Enhancement, 2(4), 348–355. https://doi.org/10.1007/s41465-018-0109-9
   Google Scholar
• Fond, G., Micoulaud-Franchi, J.-A., Brunel, L., Macgregor, A., Miot, S., Lopez, R., Richieri, R., Abbar, M., Lancon, C., & Repantis, D. (2015). Innovative mechanisms of action for pharmaceutical cognitive enhancement: A systematic review. Psychiatry Research, 229(1–2), 12–20. https://doi.org/10.1016/j.psychres.2015.07.006
   PubMed Web of Science ®Google Scholar
• Ford, J. A. (2008). Nonmedical prescription drug use among college students: A comparison between athletes and nonathletes. Journal of American College Health, 57(2), 211–220. https://doi.org/10.3200/JACH.57.2.211-220
   PubMed Web of Science ®Google Scholar
• Franke, A. G., Bagusat, C., Rust, S., Engel, A., & Lieb, K. (2014). Substances used and prevalence rates of pharmacological cognitive enhancement among healthy subjects. European Archives of Psychiatry and Clinical Neuroscience, 264(S1), 83–90. https://doi.org/10.1007/s00406-014-0537-1
   PubMedGoogle Scholar
• Franke, A. G., Bonertz, C., Christmann, M., Huss, M., Fellgiebel, A., Hildt, E., & Lieb, K. (2011). Non-medical use of prescription stimulants and illicit use of stimulants for cognitive enhancement in pupils and students in Germany. Pharmacopsychiatry, 44(2), 60–66. https://doi.org/10.1055/s-0030-1268417
   PubMed Web of Science ®Google Scholar
• Franke, A. G., Gransmark, P., Agricola, A., Schuhle, K., Rommel, T., Sebastian, A., Ballo, H. E., Gorbulev, S., Gerdes, C., Frank, B., Ruckes, C., Tuscher, O., & Lieb, K. (2017). Methylphenidate, modafinil, and caffeine for cognitive enhancement in chess: A double-blind, randomised controlled trial. European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology, 27(3), 248–260. https://doi.org/10.1016/j.euroneuro.2017.01.006
   PubMed Web of Science ®Google Scholar
• Frati, P., Kyriakou, C., Del Rio, A., Marinelli, E., Vergallo, G. M., Zaami, S., & Busardò, F. P. (2015). Smart drugs and synthetic androgens for cognitive and physical enhancement: Revolving doors of cosmetic neurology. Current Neuropharmacology, 13(1), 5–11. https://doi.org/10.2174/1570159X13666141210221750
   PubMed Web of Science ®Google Scholar
• Froestl, W., Muhs, A., & Pfeifer, A. (2012). Cognitive enhancers (nootropics). Part 1: Drugs interacting with receptors. Journal of Alzheimer's Disease, 32(4), 793–887. https://doi.org/10.3233/JAD-2012-121186
   PubMed Web of Science ®Google Scholar
• Gahr, M., Freudenmann, R. W., Hiemke, C., Kölle, M. A., & Schönfeldt-Lecuona, C. (2014). Abuse of methylphenidate in Germany: Data from spontaneous reports of adverse drug reactions. Psychiatry Research, 215(1), 252–254. https://doi.org/10.1016/j.psychres.2013.11.008
   PubMed Web of Science ®Google Scholar
• Gallucci, A. R., & Martin, R. J. (2015). Misuse of prescription stimulant medication in a sample of college students: Examining differences between varsity athletes and non-athletes. Addictive Behaviors, 51, 44–50. https://doi.org/10.1016/j.addbeh.2015.07.004
   PubMed Web of Science ®Google Scholar
• Garasic, M. D., & Lavazza, A. (2016). Moral and social reasons to acknowledge the use of cognitive enhancers in competitive-selective contexts. BMC Medical Ethics, 17(1), 18–12. https://doi.org/10.1186/s12910-016-0102-8
   PubMedGoogle Scholar
• Gilbert, B. (2015). Here’s why Adderall is taking over the world of professional gaming. https://www.businessinsider.com/how-adderall-is-used-in-esports-2015-7?r=US&IR=T
   Google Scholar
• Giurgea, C., & Salama, B. (1977). Nootropic drugs. Progress in Neuro-Psychopharmacology, 1(3–4), 235–247. https://doi.org/10.1016/0364-7722(77)90046-7
   Google Scholar
• Godfrey, J. (2009). Safety of therapeutic methylphenidate in adults: A systematic review of the evidence. Journal of Psychopharmacology (Oxford, England), 23(2), 194–205. https://doi.org/10.1177/0269881108089809
   PubMed Web of Science ®Google Scholar
• Goodman, R. (2010). Cognitive enhancement, cheating, and accomplishment. Kennedy Institute of Ethics Journal, 20(2), 145–160. https://doi.org/10.1353/ken.0.0309
   PubMed Web of Science ®Google Scholar
• Greely, H., Sahakian, B., Harris, J., Kessler, R. C., Gazzaniga, M., Campbell, P., & Farah, M. J. (2008). Towards responsible use of cognitive-enhancing drugs by the healthy. Nature, 456(7223), 702–705. https://doi.org/10.1038/456702a
   PubMed Web of Science ®Google Scholar
• Haavisto, M. (2011). Reviving the broken Marionette: Treatments for CFS/ME and Fibromyalgia, Self-Published.
   Google Scholar
• Hanstad, D., Smith, A., & Waddington, I. (2008). The establishment of the World Anti-Doping Agency: A study of the management of organizational change and unplanned outcomes. International Review for the Sociology of Sport, 43(3), 227–249. https://doi.org/10.1177/1012690208100552
   Web of Science ®Google Scholar
• Heinz, A., Kipke, R., Heimann, H., & Wiesing, U. (2012). Cognitive neuroenhancement: False assumptions in the ethical debate. Journal of Medical Ethics, 38(6), 372–375. https://doi.org/10.1136/medethics-2011-100041
   PubMed Web of Science ®Google Scholar
• Holden, J. T., Kaburakis, A., & Rodenberg, R. M. (2018). Esports: Children, stimulants and video‐gaming‐induced inactivity. Journal of Paediatrics and Child Health, 54(8), 830–831. https://doi.org/10.1111/jpc.13897
   PubMed Web of Science ®Google Scholar
• Holden, J. T., Rodenberg, R. M., & Kaburakis, A. (2017). Esports corruption: Gambling, doping, and global governance. Maryland Journal of International Law, 32(1), 236–273.
   Google Scholar
• Hunt, T. (2007). Sports, drugs and the Cold War: The conundrum of Olympic doping policy 1970–1979. Olympika: The International Journal of Olympic Studies (pp. 19–41). International Centre for Olympic Studies.
   Google Scholar
• Husain, M., & Mehta, M. A. (2011). Cognitive enhancement by drugs in health and disease. Trends in Cognitive Sciences, 15(1), 28–36. https://doi.org/10.1016/j.tics.2010.11.002
   PubMed Web of Science ®Google Scholar
• Imperatori, L. S., Milbourn, L., & Garasic, M. D. (2018). Would the use of safe, cost-effective tDCS tackle rather than cause unfairness in sports? Journal of Cognitive Enhancement, 2(4), 377–387. https://doi.org/10.1007/s41465-018-0113-0
   Google Scholar
• Jwa, A. S. (2019). Regulating the use of cognitive enhancement: An analytic framework. Neuroethics, 12(3), 293–309. https://doi.org/10.1007/s12152-019-09408-5
   Web of Science ®Google Scholar
• Ketchum, F. B. (2017). Commentary: Care, choice, and the ethical imagination. Cambridge Quarterly of Healthcare Ethics: CQ: The International Journal of Healthcare Ethics Committees, 26(4), 698–700. https://doi.org/10.1017/S0963180117000238
   PubMed Web of Science ®Google Scholar
• Kimko, H. C., Cross, J. T., & Abernethy, D. R. (1999). Pharmacokinetics and clinical effectiveness of methylphenidate. Clinical Pharmacokinetics, 37(6), 457–470. https://doi.org/10.2165/00003088-199937060-00002
   PubMed Web of Science ®Google Scholar
• Lazuras, L., Ypsilanti, A., Lamprou, E., & Kontogiorgis, C. (2017). Pharmaceutical cognitive enhancement in Greek University students: Differences between users and non-users in social cognitive variables, burnout, and engagement. Substance Use & Misuse, 52(7), 950–958. https://doi.org/10.1080/10826084.2016.1267223
   PubMed Web of Science ®Google Scholar
• Linssen, A., Vuurman, E., Sambeth, A., & Riedel, W. (2012). Methylphenidate produces selective enhancement of declarative memory consolidation in healthy volunteers. Psychopharmacology, 221(4), 611–619. https://doi.org/10.1007/s00213-011-2605-9
   PubMed Web of Science ®Google Scholar
• Lucke, J. C., Bell, S. K., Partridge, B. J., & Hall, W. D. (2011). Academic doping or Viagra for the brain? The history of recreational drug use and pharmacological enhancement can provide insight into these uses of neuropharmaceuticals EMBO Reports, 12(3), 197–201. https://doi.org/10.1038/embor.2011.15
   PubMedGoogle Scholar
• Maher, B. (2008). Poll results: Look who's doping. Nature, 452(7188), 674–675. https://doi.org/10.1038/452674a
   PubMed Web of Science ®Google Scholar
• Maier, L. J., & Schaub, M. P. (2015). The use of prescription drugs and drugs of abuse for neuroenhancement in Europe. European Psychologist, 20(3), 155–166. https://doi.org/10.1027/1016-9040/a000228
   Web of Science ®Google Scholar
• Maier, L. J., Ferris, J. A., & Winstock, A. R. (2018). Pharmacological cognitive enhancement among non-ADHD individuals—a cross-sectional study in 15 countries. The International Journal on Drug Policy, 58, 104–112. https://doi.org/10.1016/j.drugpo.2018.05.009
   PubMed Web of Science ®Google Scholar
• Maier, L. J., Haug, S., & Schaub, M. P. (2016). Prevalence of and motives for pharmacological neuroenhancement in Switzerland - Results from a national internet panel. Addiction (Abingdon, England), 111(2), 280–295. https://doi.org/10.1111/add.13059
   PubMed Web of Science ®Google Scholar
• Maier, L. J., Liechti, M. E., Herzig, F., & Schaub, M. P. (2013). To dope or not to dope: Neuroenhancement with prescription drugs and drugs of abuse among Swiss university students. PloS One, 8(11), e77967https://doi.org/10.1371/journal.pone.0077967
   PubMed Web of Science ®Google Scholar
• Malykh, A. G., & Sadaie, M. R. (2010). Piracetam and Piracetam-like drugs: from basic science to novel clinical applications to CNS disorders. Drugs, 70(3), 287–312. https://doi.org/10.2165/11319230-000000000-00000
   PubMed Web of Science ®Google Scholar
• Maslen, H., Faulmüller, N., & Savulescu, J. (2014). Pharmacological cognitive enhancement—how neuroscientific research could advance ethical debate. Frontiers in Systems Neuroscience, 8(107), 107–112. https://doi.org/10.3389/fnsys.2014.00107
   PubMedGoogle Scholar
• McCabe, S. E., Knight, J. R., Teter, C. J., & Wechsler, H. (2005). Non-medical use of prescription stimulants among US college students: Prevalence and correlates from a national survey. Addiction (Abingdon, England), 100(1), 96–106. https://doi.org/10.1111/j.1360-0443.2005.00944.x
   PubMed Web of Science ®Google Scholar
• McCabe, S. E., West, B. T., Teter, C. J., & Boyd, C. J. (2014). Trends in medical use, diversion, and nonmedical use of prescription medications among college students from 2003 to 2013: Connecting the dots. Addictive Behaviors, 39(7), 1176–1182. https://doi.org/10.1016/j.addbeh.2014.03.008
   PubMed Web of Science ®Google Scholar
• McCabe, S. E., & West, B. T. (2013). Medical and nonmedical use of prescription stimulants: Results from a national multicohort study. Journal of the American Academy of Child and Adolescent Psychiatry, 52(12), 1272–1280. https://doi.org/10.1016/j.jaac.2013.09.005
   PubMed Web of Science ®Google Scholar
• Mehta, M. A., Owen, A. M., Sahakian, B. J., Mavaddat, N., Pickard, J. D., & Robbins, T. W. (2000). Methylphenidate enhances working memory by modulating discrete frontal and parietal lobe regions in the human brain. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 20(6), RC65. https://doi.org/10.1523/JNEUROSCI.20-06-j0004.2000
   PubMed Web of Science ®Google Scholar
• Mihailov, E., & Savulescu, J. (2018). Social policy and cognitive enhancement: Lessons from chess. Neuroethics, 11(2), 115–127. https://doi.org/10.1007/s12152-018-9354-y
   PubMed Web of Science ®Google Scholar
• Pampel, F. (2007). Drugs and sport. Infobase Publishing.
   Google Scholar
• Parisotto, R. (2006). Blood sports: The inside dope on drugs in sport. Hardie Grant Books.
   Google Scholar
• Partridge, B., Lucke, J., & Hall, W. (2012). A comparison of attitudes toward cognitive enhancement and legalized doping in sport in a community sample of Australian adults. AJOB Primary Research, 3(4), 81–86. https://doi.org/10.1080/21507716.2012.720639
   Google Scholar
• Partridge, B. J., Bell, S. K., Lucke, J. C., Yeates, S., & Hall, W. D. (2011). Smart drugs “as common as coffee”: media hype about neuroenhancement. PLoS One, 6(11), e28416. https://doi.org/10.1371/journal.pone.0028416
   PubMed Web of Science ®Google Scholar
• Patra, K. (2013). Richard Sherman: I was misquoted about Adderall use. http://www.nfl.com/news/story/0ap1000000159155/article/richard-sherman-i-was-misquoted-about-adderall-use
   Google Scholar
• Pavarini, G., McKeown, A., & Singh, I. (2018). Smarter than thou, holier than thou: The dynamic interplay between cognitive and moral enhancement. Frontiers in Pharmacology, 9(1189), 1189–1113. https://doi.org/10.3389/fphar.2018.01189
   PubMedGoogle Scholar
• Peck, S., Vida, M., & Eccles, S. (2008). Adolescent pathways to adulthood drinking: Sport activity involvement is not necessarily risky or protective. Addiction, 103(s1), 69–83. https://doi.org/10.1111/j.1360-0443.2008.02177.x
   PubMedGoogle Scholar
• Petersen, M. A., Enghoff, O., & Demant, J. (2019). The uncertainties of enhancement: A mixed-methods study on the use of substances for cognitive enhancement and it’s unintended consequences. Performance Enhancement & Health, 6(3–4), 111–120. https://doi.org/10.1016/j.peh.2018.09.001
   Google Scholar
• Ram, S., Hussainy, S., Henning, M., Jensen, M., & Russell, B. (2016). Prevalence of cognitive enhancer use among New Zealand tertiary students. Drug Alcohol Rev, 35(3), 345–351. https://doi.org/10.1111/dar.12294
   PubMed Web of Science ®Google Scholar
• Randall, D. C., Shneerson, J. M., & File, S. E. (2005). Cognitive effects of modafinil in student volunteers may depend on IQ. Pharmacology Biochemistry and Behavior, 82(1), 133–139. https://doi.org/10.1016/j.pbb.2005.07.019
   PubMed Web of Science ®Google Scholar
• Repantis, D., Schlattmann, P., Laisney, O., & Heuser, I. (2010). Modafinil and methylphenidate for neuroenhancment in healthy individuals: A systematic review. Pharmacological Research, 62(3), 187–206. https://doi.org/10.1016/j.phrs.2010.04.002
   PubMed Web of Science ®Google Scholar
• Riddell, C., Jensen, C., & Carter, O. (2018). Cognitive enhancement and coping in an Australian University student sample. Journal of Cognitive Enhancement, 2(1), 63–69. https://doi.org/10.1007/s41465-017-0046-z
   Google Scholar
• Sachdeva, A., Kumar, K., & Singh Anand, K. (2015). Non-pharmacological cognitive enhancers: Current perspectives. Journal of Clinical and Diagnostic Research, 9(7), 1–6. https://doi.org/10.7860/JCDR/2015/13392.6186
   Web of Science ®Google Scholar
• Sahakian, B. J., Bruhl, A. B., Cook, J., Killikelly, C., Savulich, G., Piercy, T., Hafizi, S., Perez, J., Fernandez-Egea, E., Suckling, J., & Jones, P. B. (2015). The impact of neuroscience on society: Cognitive enhancement in neuropsychiatric disorders and in healthy people. Philosophical Transactions of the Royal Society B: Biological Sciences, 370(1677), 20140214. https://doi.org/10.1098/rstb.2014.0214
   PubMed Web of Science ®Google Scholar
• Santoni de Sio, F., Faulmüller, N., & Vincent, N. A. (2014). How cognitive enhancement can change our duties. Frontiers in Systems Neuroscience, 8(131), 131–134. https://doi.org/10.3389/fnsys.2014.00131
   PubMedGoogle Scholar
• Sattler, S. (2019). Nonmedical use of prescription drugs for cognitive enhancement as response to chronic stress especially when social support is lacking. Stress and Health: Journal of the International Society for the Investigation of Stress, 35(2), 127–137. https://doi.org/10.1002/smi.2846
   PubMed Web of Science ®Google Scholar
• Sattler, S., Forlini, C., Racine, E., & Sauer, C. (2013). Impact of contextual factors and substance characteristics on perspectives toward cognitive enhancement. PLoS One, 8(8), e71452https://doi.org/10.1371/journal.pone.0071452
   PubMed Web of Science ®Google Scholar
• Savulecu, J., Foddy, B., & Clayton, M. (2004). Why we should allow performance enhancing drugs in sport. British Journal of Sports Medicine, 38, 666–670.
   PubMed Web of Science ®Google Scholar
• Smith, A., Stewart, B., Westberg, K., & Stavros, C. (2018). Performance and image enhancing drugs and substances: Issues, influences and impacts. Routledge.
   Google Scholar
• Smith, M. E., & Farah, M. J. (2011). Are prescription stimulants “smart pills”?: The epidemiology and cognitive neuroscience of prescription stimulant use by normal healthy individuals. Psychological Bulletin, 137(5), 717–741. https://doi.org/10.1037/a0023825
   PubMed Web of Science ®Google Scholar
• Substance Abuse and Mental Health Services Administration (SAMHSA). (2008). Results from the 2007 National Survey on Drug Use and Health (NSDUH). Department of Health and Human Services Office of Applied Studies.
   Google Scholar
• Sylvester, R., & Rennie, P. (2017). The world’s fastest-growing sport: Maximizing the economic success of esports whilst balancing regulatory concerns and ensuring the protection of those involved. Gaming Law Review, 21(8), 625–629. https://doi.org/10.1089/glr2.2017.21811
   Google Scholar
• Thirsk, R., Kuipers, A., Mukai, C., & Williams, D. (2009). The space-flight environment: The International Space Station and beyond. CMAJ: Canadian Medical Association Journal / Journal de L'Association Medicale Canadienne, 180(12), 1216–1220. https://doi.org/10.1503/cmaj.081125
   PubMed Web of Science ®Google Scholar
• Thompson, H. (2012). Performance enhancement: Superhuman athletes. Nature, 487(7407), 287–289. https://doi.org/10.1038/487287a
   PubMed Web of Science ®Google Scholar
• Tully, J., Montgomery, C., Maier, L. J., & Sumnall, H. R. (2019). 9 Estimated prevalence, effects and potential risks of substances used for cognitive enhancement. Human Enhancement Drugs.
   Google Scholar
• Turner, D. C., Robbins, T. W., Clark, L., Aron, A. R., Dowson, J., & Sahakian, B. J. (2003). Cognitive enhancing effects of modafinil in healthy volunteers. Psychopharmacology, 165(3), 260–269. https://doi.org/10.1007/s00213-002-1250-8
   PubMed Web of Science ®Google Scholar
• Vargo, E. J., & Petróczi, A. (2016). “It was me on a good day”: Exploring the smart drug use phenomenon in England. Frontiers in Psychology, 7, 779. https://doi.org/10.3389/fpsyg.2016.00779
   PubMed Web of Science ®Google Scholar
• Vargo, E. J., James, R. A., Agyeman, K., MacPhee, T., McIntyre, R., Ronca, F., & Petróczi, A. (2014). Perceptions of assisted cognitive and sport performance enhancement among university students in England. Performance Enhancement & Health, 3(2), 66–77. https://doi.org/10.1016/j.peh.2015.02.001
   Google Scholar
• Volkow, N. D., & Swanson, J. M. (2003). Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD. The American Journal of Psychiatry, 160(11), 1909–1918. https://doi.org/10.1176/appi.ajp.160.11.1909
   PubMed Web of Science ®Google Scholar
• Volkow, N. D., Wang, G. J., Tomasi, D., Kollins, S. H., Wigal, T. L., Newcorn, J. H., Telang, F. W., Fowler, J. S., Logan, J., Wong, C. T., & Swanson, J. M. (2012). Methylphenidate-elicited dopamine increases in ventral striatum are associated with long-term symptom improvement in adults with attention deficit hyperactivity disorder. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 32(3), 841–849. https://doi.org/10.1523/JNEUROSCI.4461-11.2012
   PubMed Web of Science ®Google Scholar
• Vrecko, S. (2013). Just how cognitive is “cognitive enhancement”? On the significance of emotions in university students' experiences with study drugs. AJOB Neuroscience, 4(1), 4–12. https://doi.org/10.1080/21507740.2012.740141
   PubMedGoogle Scholar
• Wagner, N.-F., Robinson, J., & Wiebking, C. (2015). The ethics of neuroenhancement: Smart drugs, competition and society. International Journal of Technoethics, 6(1), 1–20. https://doi.org/10.4018/ijt.2015010101
   Web of Science ®Google Scholar
• Wichstrom, T., & Wichstrom, L. (2009). Does sport participation during adolescence prevent later alcohol, tobacco and cannabis use. Addiction, 104(1), 138–149.
   PubMed Web of Science ®Google Scholar
• Wilson, G. S., Pritchard, M. E., & Schaffer, J. (2004). Athletic status and drinking behavior in college students: The influence of gender and coping styles. Journal of American College Health, 52(6), 269–273. https://doi.org/10.3200/JACH.52.6.269-275
   PubMed Web of Science ®Google Scholar
• Winder-Rhodes, S., Chamberlain, S., Idris, M., Robbins, T., Sahakian, B., & Muller, U. (2010). Effects of modafinil and prazosin on cognitive and physiological functions in healthy volunteers. Journal of Psychopharmacology (Oxford, England), 24(11), 1649–1657. https://doi.org/10.1177/0269881109105899
   PubMed Web of Science ®Google Scholar
• Wolff, W., & Brand, R. (2013). Subjective stressors in school and their relation to neuroenhancement: A behavioral perspective on students’ everyday life doping. Substance Abuse Treatment, Prevention, and Policy, 8(1), 23. https://doi.org/10.1186/1747-597X-8-23
   PubMedGoogle Scholar
• World Anti-Doping Agency (WADA). (2019). International standard therapeutic use exemptions. https://www.wada-ama.org/sites/default/files/resources/files/istue_2019_en_new.pdf.
   Google Scholar
• World Anti-Doping Agency (WADA). (2020). International standard prohibited list 2020. https://www.wada-ama.org/sites/default/files/wada_2020_english_prohibited_list_0.pdf
   Google Scholar
• World Bridge Federation (WBF). (2015). World Bridge Federation [WBF] Anti-doping rules, approved by the Executive Council of the World Bridge Federation at their meeting held on: 15th October 2014 (based upon the 2015 code and confirmed by WADA on 17 November 2014), Effective as of 1 January 2015. Retrieved May 8, 2020, from http://www.worldbridge.org/rules-regulations/anti-doping-regulations/
   Google Scholar